Monday, 20 Jan 2020

You are here

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

A prospective registry of CTD and PSV patients enrolled 2140 patients (1534 with CTD, 606 with PSV) between 1999 and 2015. Cases were matched against 15 sex and age matched controls from the Norwegian National Population Registry. 

After a mean follow-up time of 9 years, 279 patients (13%) died, compared with 9% of 32086 controls (P < 0.001).

Lowest 10 year survival was seen in diffuse cutaneous systemic sclerosis (dcSSc) at 60%; this was followed by  73% in anti-synthetase syndrome (ASS) and 75% in limited cutaneous SSc patients.

In the CTD and primary systemic vasculitis (PSV) patients, the highest standard mortality ratios (SMRs) included:

  • dcSSc SMR = 5.8)
  • ASS SMR = 4.1
  • Takayasu arteritis SMR = 2.5
  • ANCA-associated vasculitis SMR = 1.5)

Overall, the major causes of death were cardiovascular disease (CTD 27%, PSV 28%), neoplasms (CTD 25%, PSV 27%), chronic respiratory disease (CTD 20%, PSV10%) and infections (CTD 9%, PSV 16%).

These data call for strategies to address the excess mortality seen among patients with CTD and PSV. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

TULIP2 - Anifrolumab Succeeds in Lupus

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Steroids Up the Risk of Organ Damage in SLE

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.

Treatment of Statin-induced anti-HMGCR myopathy

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of triple steroid/IVIG/SSI was very efficacious in induction.

Best of 2019 - 2019 EULAR Guidelines on Antiphospholipid Syndrome Management

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.

Best of 2019 - New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.